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Abstract
Purpose: The objective of this study was to correlate the presence and distribution of cerebral microbleeds in Alzheimer’s
disease patients with cerebrospinal fluid biomarkers (amyloid-beta and phosphorylated tau 181 protein levels) and cognitive
decline by using susceptibility-weighted imaging magnetic resonance sequences at 1.5 T.
Material and methods: Fifty-four consecutive Alzheimer’s disease patients underwent brain magnetic resonance imaging at
1.5 T to assess the presence and distribution of cerebral microbleeds on susceptibility-weighted imaging images. The
images were analyzed in consensus by two neuroradiologists, each with at least 10 years’ experience. Dementia severity
was assessed with the Mini-Mental State Examination score.
A multiple regression analysis was performed to assess the associations between the number and location of cerebral
microbleed lesions with the age, sex, duration of the disease, cerebrospinal fluid amyloid-beta and phosphorylated tau
181 protein levels, and cognitive functions.
Results: A total of 296 microbleeds were observed in 54 patients; 38 patients (70.4%) had lobar distribution, 13 patients
(24.1%) had non-lobar distribution, and the remaining three patients (5.6%) had mixed distribution, demonstrating that
Alzheimer’s disease patients present mainly a lobar distribution of cerebral microbleeds.
The age and the duration of the disease were correlated with the number of lobar cerebral microbleeds (P< 0.001).
Cerebrospinal fluid amyloid-beta, phosphorylated tau 181 protein levels, and cognitive decline were correlated with the
number of lobar cerebral microbleeds in Alzheimer’s disease patients (P< 0.001).
Conclusion: Lobar distribution of cerebral microbleeds is associated with Alzheimer’s disease and the number of lobar
cerebral microbleeds directly correlates with cerebrospinal fluid amyloid-beta and phosphorylated tau 181 protein levels
and with the cognitive decline of Alzheimer’s disease patients.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegen-
erative disorder that aﬀects the brain in adult patients
who typically remain asymptomatic for a considerable
duration of time before demonstrating clinical evidence
of cognitive decline.1,2
Cerebral amyloid angiopathy (CAA) is commonly
observed in pathology analysis of AD-aﬀected brains
and it is associated with lobar distribution of cerebral
microbleeds (CMBs), which aﬀect cognitive function.3–5
CMBs are presumed to reﬂect focal hemosiderin
deposits in the brain that are caused by leakage of
red blood cells from small blood vessels.6,7
CMBs can be visualized on T2*-weighted gradient-
recalled-echo (GRE) magnetic resonance (MR)
imaging sequences, as small foci of decreased signal
intensity.3,8
In recent years, the introduction of susceptibility-
weighted imaging (SWI) MR sequences has improved
CMB detection in MR imaging.
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The SWI sequence is a velocity compensated high-
resolution 3D gradient-echo sequence that uses magni-
tude and ﬁltered-phase information to create a new
contrast.9–11 As a result, CMBs are more sensitively
detected by SWI compared with T2*-weighted
GRE.3,12–14
A previous study4 based on 3 T MR imaging and
T2* GRE sequence demonstrated an association
between lobar distributed CMBs and cerebrospinal
ﬂuid (CSF) amyloid-beta (A) levels as well as with
CSF phosphorylated tau 181 protein (p-tau) levels
and the presence of cognitive decline in AD patients.
The aim of this study was to assess the presence and
distribution of CMBs with SWI MR sequences imple-
mented in a more widely available 1.5 T MR unit and
to correlate the presence and distribution of CMBs with
CSF biomarkers of AD and with cognitive decline in
AD patients.
Material and methods
Patient population
We included 54 consecutive patients (20men, 34 women;
mean age: 76.8 5.2 years) diagnosed as having AD
(mean duration of the disease: 7.2 3.7 years).
The diagnosis was established according to the cri-
teria for probable AD as proposed by the National
Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease
and Related Disorders Association.15
Exclusion criteria were: previous stroke or head
trauma; cancer history; severe cardiac, renal, or hepatic
disease; recent history of infection or inﬂammatory dis-
ease. Dementia severity was assessed with the Mini-
Mental State Examination.16 Demographic data are
presented in Table 1.
Patients underwent lumbar puncture to obtain CSF
samples for quantifying levels of CSF A and p-tau.
The institutional review board of our institution
approved this retrospective study and written informed
consent was obtained from all patients.
MR imaging
All patients underwent MR examination between
January 2015 and May 2016. All MR examinations
were performed on a 1.5 T MR scanner (Achieva,
Philips Medical Systems, Best, The Netherlands).
MR imaging protocol included axial and sagittal fast-
spin echo (FSE) T2W (5100/110 [TR/TE]) images, axial
ﬂuid-attenuated inversion-recovery (FLAIR) (8000/
140/2400 [TR/TE/TI]) images, along with axial, sagittal,
and coronal non-enhanced and contrast-enhanced
(0.1mmol/Kg gadobutrol -Gadovist, Bayer, Germany)
FSE T1W (650/15 [TR/TE]) images with a ﬁeld of view
(FOV) of 22 cm, matrix 512 512, slice thickness 5mm,
intersection gap 1mm, number of excitations 2.
Susceptibility weighted imaging (SWI) sequences
were obtained using a technique that combines a
long-TE high-resolution fully ﬂow-compensated 3D
GRE sequence with ﬁltered phase information in each
voxel, as previously described.9–11
The SWI images (3D GRE 24/34 [TR/TE], ﬂip angle
10) were obtained with a FOV of 22 cm, matrix
256 512, slice thickness 1.2mm, gap 0mm, number of
excitations 1 and acquisition time 5.15min. Subsequently,
the SWI sequences were reconstructed to obtain images
of 5mm thickness, 1mm intersection gap, oriented in
the axial plane similar to that of FSE images.
Calciﬁcations of the basal ganglia and deep cerebel-
lar nuclei were considered as normal ﬁndings if present
and not taken into account during the review of the
images. None of the patients had disorders of cal-
cium/phosphate metabolism.
Image analysis
The images were analyzed in consensus by two neuror-
adiologists, each with at least 10 years experience.
Images, presented in random order, were analyzed
for the presence and location of the CMB lesions.
CMBs were deﬁned as small hypointense lesions
within the brain parenchyma that measured less than
10mm on the SWI images.
The locations of the microbleeds were subdivided
into: non-lobar, if located in the basal ganglia, thalami,
brain stem, or cerebellum; lobar, if located in one of the
four cerebral lobes: frontal, parietal, occipital, and tem-
poral; mixed, in the case of CMBs distributed in both
lobar and non-lobar locations.
The two neuroradiologists recorded the location and
number of lesions seen on SWI images on a PACS
system (Agfa HealthCare GmbH -Bonn).
Statistical analysis
The ordinary least-squares multiple regression analysis
was performed to assess the associations between the
number and location of CMB lesions (dependent vari-
able) with the patient’s age and sex, duration of the
disease, CSF A, p-tau levels, and cognitive functions
(independent variables). Diﬀerences for a P value
of< .05 were considered statistically signiﬁcant.
Statistical analysis was performed using the statistical
software package SPSS (SPSS, Chicago, IL).
Table 1. Characteristics of AD patients.
Variables Number
Number of patients 54
Mean age (SD), years 76.8 (5.2)
Sex, male/female 20/34
Mean duration of AD (SD), years 7.2 (3.7)
MMSE score (SD) 18.3 (8.5)
AD: Alzheimer’s disease; MMSE: Mini-Mental State Examination.
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Results
CMBs were demonstrated as small, rounded, hypoin-
tense lesions within the brain parenchyma that mea-
sured less than 10mm on the SWI images.
A total of 296 microbleeds were observed in 54
patients; 38 patients (70.4%) had lobar distribution,
13 patients (24.1%) had non-lobar distribution and
the remaining three patients (5.6%) had mixed distri-
bution (see Table 2 and Figures 1–3).
The mean count of microbleeds was 5.4 per patient
and the median was four CMBs per patient. The fre-
quency of the number of CMBs was as follow: seven
patients (13%) had one microbleed, 11 patients (20.4%)
had two microbleeds, eight patients (14.8%) had three
microbleeds, eight patients (14.8%) had four micro-
bleeds, four patients (7.4%) had ﬁve microbleeds and
the remaining 16 patients (29.6%) had more than ﬁve
microbleeds (Table 3).
The correlation analysis showed that the age of the
patients and the duration of the disease were
signiﬁcantly correlated with the number of lobar
CMBs (P< 0.001, age coeﬃcient .46, duration of the
disease coeﬃcient .58).
A signiﬁcant correlation was found between the CSF
A levels and the number of lobar CMBs (P< 0.001,
coeﬃcient .32).
Non-lobar microbleeds were not associated with
CSF A levels.
A direct correlation was found between the number
of lobar CMBs and CSF p-tau levels (P< 0.001, coef-
ﬁcient .35).
Non-lobar microbleeds were not correlated with
CSF p-tau levels.
Using a generalized linear mixed-eﬀects model
adjusted for covariates, including CSF A levels, age,
sex, and disease duration, the number of lobar micro-
bleeds was signiﬁcantly associated with the MMSE
score (P< 0.001, coeﬃcient .37).
Non-lobar microbleeds were not associated with
change in MMSE score (P< 0.001). Results are sum-
marized in Table 4.
Discussion
The results of our study conﬁrm that lobar distribution
of microbleeds is associated with AD as reported in
previous publications.17,18 In particular, of the 54 AD
patients reviewed, 38 (70.4%) had a lobar distribution
of the microbleeds, 13 (24.1%) had a non-lobar distri-
bution and the remaining three (5.6%) had a mixed
distribution (Table 2).
In accordance with results of previous publications,
which showed lower CSF A levels in AD patients with
lobar microbleeds,4,19,20 we likewise found a signiﬁcant
correlation between CSF A levels and the number of
lobar CMBs (P< 0.001, coeﬃcient .32), which means
Figure 1. Lobar distributed cerebral microbleeds in Alzheimer’s disease patient. (ab) Axial SWI MR images show multiple small,
rounded, hypointense cerebral microbleeds bilaterally in the parietal and frontal lobes (arrowhead).
SWI: susceptibility-weighted imaging; MR: magnetic resonance.
Table 2. Number of CMBs subdivided by location.
Location Number of patients Number of CMBs %
Lobar 38 238 70.4
Non-lobar 13 46 24
Mixed 3 12 5.6
Total 54 296 100
Location: Lobar – CMBs located in one of the four cerebral lobes: frontal,
parietal, occipital, and temporal; Non-lobar – CMBs located in the basal
ganglia, thalami, brain stem, or cerebellum; Mixed – mixed distribution of
the CMBs in both lobar and non-lobar locations.
CMBs: cerebral microbleeds.
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Figure 2. Non-lobar distributed cerebral microbleed in Alzheimer’s disease patient. Axial SWI MR image shows a small, rounded,
hypointense cerebral microbleed in the left basal ganglia (arrowhead).
SWI: susceptibility-weighted imaging; MR: magnetic resonance.
Figure 3. Mixed distribution of cerebral microbleeds in Alzheimer’s disease patient. (ab) Axial SWI MR images show small, rounded,
hypointense cerebral microbleeds in the (a) left cerebellar hemisphere and in the (b) left frontal lobe (arrowhead).
SWI: susceptibility-weighted imaging; MR: magnetic resonance.
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that greater brain amyloidosis is associated with
increasing numbers of lobar CMBs.
It should be noted that previous investigators4 were
unable to establish statistical signiﬁcance for this cor-
relation. A possible explanation for the signiﬁcant cor-
relation found in our study may relate to a substantial
technical diﬀerence between the studies, as we used
SWI sequences as opposed to the T2* GRE sequences
used by others. SWI sequences have been demonstrated
to be superior to T2* GRE sequences, the former
having higher sensitivity in demonstrating CMBs.21,22
Such increased sensitivity of SWI for visualization of
CMBs probably leads to detection of a greater number
of microbleeds in our study and thus accounts for the
statistically signiﬁcant correlation with the lower CSF
A levels observed in our AD patients.
An association between lobarmicrobleeds and elevated
CSF p-tau level was also demonstrated (P< 0.001, coeﬃ-
cient .35), implying that a larger number of lobar CMBs
are observed in patients with higher CSF p-tau levels.
This correlation may reﬂect the notion that microbleeds
are the imaging expression of damaged microvasculature,
or that CMBs may lead to cerebral inﬂammation, which
results in increased tau pathology.4,23
Non-lobar microbleeds were not associated with
CSF A and p-tau levels.
The patient’s age and the duration of the disease
were correlated with the number of lobar CMBs
(P< 0.001, age coeﬃcient .46, duration of the disease
coeﬃcient .58), and a correlation analysis adjusted for
CSF A levels, age, sex, and duration of the disease
showed that the number of lobar microbleeds was sig-
niﬁcantly associated with the MMSE score, implying
that worsening cognitive function is associated with
the presence and number of lobar CMBs (P< 0.001,
coeﬃcient .37).
This result conﬁrms conclusions reached by previous
publications which have shown a direct correlation
between the extent of amyloid angiopathy and the
degree of memory and cognitive decline in AD patients
with lobar microbleeds.4,18,24,25
Non-lobar microbleeds were not associated with
change in MMSE score (P< 0.001), as demonstrated
in previous studies.4,26
One of the limitations of our study is that it lacked a
comparison between T2* GRE sequences and SWI
sequences in the detection of CMBs. However, this
aspect was beyond the purpose of our study, as the
higher sensitivity of SWI sequences for detection of
CMBs had already been demonstrated by several pre-
vious publications.21,22
Conclusion
Improved detection of CMBs with SWI sequences may
contribute to more accurate identiﬁcation of AD
patients, who typically present a lobar distribution of
CMBs.
The number of lobar CMBs is correlated to CSF A
and p-tau levels and with the degree of cognitive decline
of AD patients.
Our results should be carefully evaluated as our
sample population was relatively homogeneous, result-
ing in limited generalizability, and further validation in
a larger prospective population is required.
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Table 3. Frequency of the number of CMBs seen on SWI sequence
in AD patients.
Number
of CMBs
Number
of patients
Total number
of CMBs %
1 7 7 13.0
2 11 22 20
3 8 24 14.8
4 8 32 14.8
5 4 20 7.4
6 3 18 5.6
7 1 7 1.9
8 2 16 3.7
9 1 9 1.9
11 1 11 1.9
12 1 12 1.9
13 1 13 1.9
14 2 28 3.7
17 1 17 1.9
18 1 18 1.9
21 2 42 3.7
Total 54 296 100.0
SWI: susceptibility-weighted imaging; AD: Alzheimer’s disease; CMBs: cere-
bral microbleeds.
Table 4. Association of number of CMBs with age, duration of AD,
CSF biomarkers, and cognitive function measured with MMSE
score.
Variables Coefficient P value
Age .46 P< 0.001
Duration of AD .58 P< 0.001
CSF A level .32 P< 0.001
CSF p-tau level .35 P< 0.001
MMSE score .37 P< 0.001
CMBs: cerebral microbleeds; AD: Alzheimer’s disease; CSF: cerebrospinal
fluid; A: amyloid-beta; p-tau: phosphorylated tau 181 protein; MMSE:
Mini-Mental State Examination.
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